Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for Postoperative Inflammation
NCT05180318Phase 4Withdrawn
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of esketamine in post-operative inflammation, immunosuppression. Planned start Oct 2024; status: withdrawn.
02
Drugs
esketamine
03
Conditions
post-operative inflammationimmunosuppression
Beyond the preview
Go deeper on NCT05180318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05180318.